Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
PaperCitations, authors & open-access status
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 315 citations, 2022 year and hybrid oa status.
315
Citations
2022
Year
hybrid
OA Status